Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa
Open Access
- 1 December 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (12) , 4920-4927
- https://doi.org/10.1128/aac.49.12.4920-4927.2005
Abstract
Suppression of resistance in a dense Pseudomonas aeruginosa population has previously been shown with optimized quinolone exposures. However, the relevance to β-lactams is unknown. We investigated the bactericidal activity of meropenem and its propensity to suppress P. aeruginosa resistance in an in vitro hollow-fiber infection model (HFIM). Two isogenic strains of P. aeruginosa (wild type and an AmpC stably derepressed mutant [MIC = 1 mg/liter]) were used. An HFIM inoculated with approximately 1 × 108 CFU/ml of bacteria was subjected to various meropenem exposures. Maintenance doses were given every 8 h to simulate the maximum concentration achieved after a 1-g dose in all regimens, but escalating unbound minimum concentrations (Cmins) were simulated with different clearances. Serial samples were obtained over 5 days to quantify the meropenem concentrations, the total bacterial population, and subpopulations with reduced susceptibilities to meropenem (>3× the MIC). For both strains, a significant bacterial burden reduction was seen with all regimens at 24 h. Regrowth was apparent after 3 days, with the Cmin/MIC ratio being ≤1.7 (time above the MIC, 100%). Selective amplification of subpopulations with reduced susceptibilities to meropenem was suppressed with a Cmin/MIC of ≥6.2 or by adding tobramycin to meropenem (Cmin/MIC = 1.7). Investigations that were longer than 24 h and that used high inocula may be necessary to fully evaluate the relationship between drug exposures and the likelihood of resistance suppression. These results suggest that the Cmin/MIC of meropenem can be optimized to suppress the emergence of non-plasmid-mediated P. aeruginosa resistance. Our in vitro data support the use of an extended duration of meropenem infusion for the treatment of severe nosocomial infections in combination with an aminoglycoside.Keywords
This publication has 32 references indexed in Scilit:
- Bacterial‐Population Responses to Drug‐Selective Pressure: Examination of Garenoxacin's Effect onPseudomonas aeruginosaThe Journal of Infectious Diseases, 2005
- Comparison of β-lactams in counter-selecting resistance of Pseudomonas aeruginosaDiagnostic Microbiology and Infectious Disease, 2005
- Modelling time–kill studies to discern the pharmacodynamics of meropenemJournal of Antimicrobial Chemotherapy, 2005
- Selection of a Moxifloxacin Dose That Suppresses Drug Resistance inMycobacterium tuberculosis,by Use of an In Vitro Pharmacodynamic Infection Model and Mathematical ModelingThe Journal of Infectious Diseases, 2004
- Differential Impact of MexB Mutations on Substrate Selectivity of the MexAB-OprM Multidrug Efflux Pump of Pseudomonas aeruginosaJournal of Bacteriology, 2004
- Pharmacodynamics of S-3578, a Novel Cephem, in Murine Lung and Systemic Infection ModelsAntimicrobial Agents and Chemotherapy, 2004
- Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection modelJournal of Antimicrobial Chemotherapy, 2003
- Multidrug Efflux Systems Play an Important Role in the Invasiveness of Pseudomonas aeruginosa The Journal of Experimental Medicine, 2002
- Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa : Novel Agents for Combination TherapyAntimicrobial Agents and Chemotherapy, 2001
- -Lactamase Lability and Inducer Power of Newer -Lactam Antibiotics in Relation to Their Activity Against -Lactamase-Inducibility Mutants of Pseudomonas aeruginosaThe Journal of Infectious Diseases, 1987